Literature DB >> 17179221

Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin.

Paul R Hess1, Carie Barnes, Matthew D Woolard, Michael D L Johnson, John M Cullen, Edward J Collins, Jeffrey A Frelinger.   

Abstract

CD8+ cytotoxic T lymphocytes (CTLs) are important effector cells responsible for tissue destruction in several autoimmune and allograft-related diseases. To discover if pathogenic T cells could be selectively deleted, we investigated the ability of a toxin coupled to major histocompatibility complex (MHC) class I tetramers to kill antigen-specific CD8+ T cells. H2-D(b) tetramers were assembled using streptavidin conjugated to the ribosome-inactivating protein (RIP) saporin (SAP). These tetramers inhibited ribosome activity in vitro, retained the T-cell receptor (TCR)-binding specificity of their nontoxic counterparts, and were internalized by 100% of target cells, leading to cell death in 72 hours. Cytotoxicity was dependent on the tetramer dose and avidity for the T cell. A single injection of the SAP-coupled tetramer eliminated more than 75% of cognate, but not control, T cells. This work demonstrates the therapeutic potential of cytotoxic tetramers to selectively eradicate pathogenic clonotypes while leaving overall T-cell immunity intact.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17179221      PMCID: PMC1852243          DOI: 10.1182/blood-2006-06-028001

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

Review 1.  Long-term challenges of immunosuppression in pediatric patients.

Authors:  D A Kelly
Journal:  Transplant Proc       Date:  2005-05       Impact factor: 1.066

2.  Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation.

Authors:  C B Drachenberg; D K Klassen; M R Weir; A Wiland; J C Fink; S T Bartlett; C B Cangro; S Blahut; J C Papadimitriou
Journal:  Transplantation       Date:  1999-08-15       Impact factor: 4.939

3.  Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis.

Authors:  Mandy L Ford; Brian D Evavold
Journal:  Eur J Immunol       Date:  2005-01       Impact factor: 5.532

Review 4.  Antithymocyte globulin for prevention of graft-versus-host disease.

Authors:  Andrea Bacigalupo
Journal:  Curr Opin Hematol       Date:  2005-11       Impact factor: 3.284

5.  Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

Authors:  John P Leonard; Morton Coleman; Jamie Ketas; Michelle Ashe; Jennifer M Fiore; Richard R Furman; Ruben Niesvizky; Tsiporah Shore; Amy Chadburn; Heather Horne; Jacqueline Kovacs; Cliff L Ding; William A Wegener; Ivan D Horak; David M Goldenberg
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

6.  Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide.

Authors:  Bingye Han; Pau Serra; Abdelaziz Amrani; Jun Yamanouchi; Athanasius F M Marée; Leah Edelstein-Keshet; Pere Santamaria
Journal:  Nat Med       Date:  2005-05-22       Impact factor: 53.440

Review 7.  Chronic graft-versus-host disease.

Authors:  Mitchell E Horwitz; Keith M Sullivan
Journal:  Blood Rev       Date:  2005-04-07       Impact factor: 8.250

8.  Peripheral "CD8 tuning" dynamically modulates the size and responsiveness of an antigen-specific T cell pool in vivo.

Authors:  Robert Maile; Catherine A Siler; Samantha E Kerry; Katherine E Midkiff; Edward J Collins; Jeffrey A Frelinger
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

9.  Memory CD8 T cells require CD8 coreceptor engagement for calcium mobilization and proliferation, but not cytokine production.

Authors:  Samantha E Kerry; Robert Maile; Edward J Collins; Jeffrey A Frelinger
Journal:  Immunology       Date:  2005-01       Impact factor: 7.397

10.  Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.

Authors:  A J Coles; M G Wing; P Molyneux; A Paolillo; C M Davie; G Hale; D Miller; H Waldmann; A Compston
Journal:  Ann Neurol       Date:  1999-09       Impact factor: 10.422

View more
  18 in total

1.  Targeting Anti-Insulin B Cell Receptors Improves Receptor Editing in Type 1 Diabetes-Prone Mice.

Authors:  Rachel H Bonami; James W Thomas
Journal:  J Immunol       Date:  2015-10-02       Impact factor: 5.422

Review 2.  Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases.

Authors:  Chunsong Yu; Jingchao Xi; Meng Li; Myunggi An; Haipeng Liu
Journal:  Bioconjug Chem       Date:  2017-12-06       Impact factor: 4.774

Review 3.  Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis.

Authors:  Mark M Davis; John D Altman; Evan W Newell
Journal:  Nat Rev Immunol       Date:  2011-07-15       Impact factor: 53.106

4.  Toxin-coupled MHC class I tetramers can specifically ablate autoreactive CD8+ T cells and delay diabetes in nonobese diabetic mice.

Authors:  Benjamin G Vincent; Ellen F Young; Adam S Buntzman; Rosemary Stevens; Thomas B Kepler; Roland M Tisch; Jeffrey A Frelinger; Paul R Hess
Journal:  J Immunol       Date:  2010-03-10       Impact factor: 5.422

Review 5.  The use of peptide-major-histocompatibility-complex multimers in type 1 diabetes mellitus.

Authors:  Greg S Gojanovich; Sabrina L Murray; Adam S Buntzman; Ellen F Young; Benjamin G Vincent; Paul R Hess
Journal:  J Diabetes Sci Technol       Date:  2012-05-01

Review 6.  Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'.

Authors:  Christian Schütz; Mathias Oelke; Jonathan P Schneck; Andreas Mackensen; Martin Fleck
Journal:  Immunotherapy       Date:  2010-07       Impact factor: 4.196

7.  Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.

Authors:  Christian Schütz; Martin Fleck; Andreas Mackensen; Alessia Zoso; Dagmar Halbritter; Jonathan P Schneck; Mathias Oelke
Journal:  Blood       Date:  2007-12-20       Impact factor: 22.113

Review 8.  Tricks with tetramers: how to get the most from multimeric peptide-MHC.

Authors:  Linda Wooldridge; Anna Lissina; David K Cole; Hugo A van den Berg; David A Price; Andrew K Sewell
Journal:  Immunology       Date:  2009-02       Impact factor: 7.397

9.  Deletion of naïve T cells recognizing the minor histocompatibility antigen HY with toxin-coupled peptide-MHC class I tetramers inhibits cognate CTL responses and alters immunodominance.

Authors:  Sabrina M Hess; Ellen F Young; Keith R Miller; Benjamin G Vincent; Adam S Buntzman; Edward J Collins; Jeffrey A Frelinger; Paul R Hess
Journal:  Transpl Immunol       Date:  2013-10-23       Impact factor: 1.708

10.  T-cell reconstitution without T-cell immunopathology in two models of T-cell-mediated tissue destruction.

Authors:  Pablo Penaloza-MacMaster; David Masopust; Rafi Ahmed
Journal:  Immunology       Date:  2009-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.